Harvard Bioscience closes $40M debt refinancing with BroadOak; extends maturity to 2029, appoints new director

HARVARD BIOSCIENCE INC

Enters $40M senior secured credit facility (Term A $10M, Term B $22.5M, Term C $7.5M convertible at $1.00) maturing Dec 17, 2029
Issues warrants to purchase 2M shares of common stock at $0.50 per share; proceeds repay existing Citizens Bank credit facility
Quarterly amortization on Term A/B begins Dec 31, 2027; amortization and maturity can extend 1 year upon EBITDA milestone
Appoints Bill Snider (BroadOak Partner) to Board and Compensation Committee; will form Product, Operations & Scientific Advisory Board

item 1.01 item 1.02 item 2.03 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

HARVARD BIOSCIENCE INC incurred term loan of $10.0 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.

Instrument: term loan
Principal: $10.0 million
Counterparty: BroadOak Income Fund, L.P.
Rate: greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree
Maturity: December 17, 2029
Event: incurrence

Exact text from the filing

The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan”

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

HARVARD BIOSCIENCE INC incurred convertible notes of $7.5 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.

Instrument: convertible notes
Principal: $7.5 million
Counterparty: BroadOak Income Fund, L.P.
Rate: greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree
Maturity: December 17, 2029
Event: incurrence

Exact text from the filing

The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan”

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

HARVARD BIOSCIENCE INC incurred term loan of $22.5 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.

Instrument: term loan
Principal: $22.5 million
Counterparty: BroadOak Income Fund, L.P.
Rate: greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree
Maturity: December 17, 2029
Event: incurrence

Exact text from the filing

The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan”

View on SEC.gov

309 debt financings filed in the last 30 days. Browse all debt financings →

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR

accession 0001171843-25-007972

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.